The nation's largest pharmacy benefit manager plans to control costs from new cholesterol drugs through discounts and restricting use.» Read More
Spark Therapeutics plans to file for U.S. regulatory approval next year for the first gene therapy product on the market in the U.S.
MSF is leaving Kunduz after an airstrike on its hospital there on Saturday that killed 22 people, the NYT reports.
Morgan Stanley analyzed the drug pricing issue and found which companies are the best and worst positioned in a note sent to clients on Thursday.
Many companies at risk of the tax on high-cost health plans intend to avoid the levy.
After a string of young soccer players fall ill, June Leahy searches for answers on turf that could have caused her daughter's death, says NBC News
Doctors outside of insurance plan networks charge several times what Medicare would pay.
The fight for Planned Parenthood funding is far from over, says patient and advocate Dayna Ferris-Fisher.
Biotech stocks surged on Wednesday, and according to one trader, there are more gains ahead.
The real problem with biotech has to do with the size of biotech firms, says industry CEO Robert Mulroy. Here's why.
Sixty percent of people oppose the Obamacare levy on high-cost health plans — at first.
The most popular prescription drug plans will see an average price hike of 8 percent next year.
With the IBB performing poorly and increased confusion in the biotech market, is it time for investors to be bullish?
Hillary Clinton will speak out against the so-called Cadillac tax on certain health care plans. The NYT reports.
Many women with early-stage breast cancer can skip chemotherapy without hurting their odds of beating the disease.
Turing Pharmaceuticals may have been an egregious example of overnight drug price hikes, but it's not the only one raising eyebrows.
Democrats are pressing a Republican committee chairman to force Valeant to turn over documents tied to price hikes imposed earlier this year.
JPMorgan reached out to fund managers to find out their current concerns and analyze the prospects for the biotech sector.
Biotechnology stocks deepened their rout Friday, as fears of drugs prices continued to mount.
John Maraganore of Alnylam Pharmaceuticals tells CNBC his industry focuses on innovation, not pushing prices on decades-old drugs higher to make a profit.
Most companies now offer health coverage that requires employees to pay an annual deductible before insurance kicks in, and the size of that deductible has soared in the past decade, a study finds.
Get the best of CNBC in your inbox